Literature DB >> 27020858

NRF2 Intensifies Host Defense Systems to Prevent Lung Carcinogenesis, but After Tumor Initiation Accelerates Malignant Cell Growth.

Hironori Satoh1, Takashi Moriguchi2, Daisuke Saigusa3, Liam Baird4, Lei Yu4, Hirofumi Rokutan5, Keiko Igarashi5, Masahito Ebina6, Tatsuhiro Shibata5, Masayuki Yamamoto2.   

Abstract

Nrf2 activation promotes resistance to chemical carcinogenesis in animal models, but activating mutations in Nrf2 also confer malignant characters to human cells by activating antioxidative/detoxifying enzymes and metabolic reprogramming. In this study, we examined how these contradictory activities of Nrf2, cancer chemoprevention and cancer cell growth enhancement, can be reconciled in an established mouse model of urethane-induced lung carcinogenesis. Using Keap1-knockdown (kd) mice, which express high levels of Nrf2, we found that urethane was rapidly excreted into the urine, consistent with an upregulation in the expression of urethane detoxification genes. Consequently, urethane-induced tumors were significantly smaller and less frequent in Keap1-kd mice than in wild-type mice. In contrast, tumor cells derived from Keap1-kd mice and transplanted into nude mice exhibited higher tumorigenicity compared with cells derived from wild-type mice. To identify the factors contributing to the tumor growth phenotype in the transplantation model, we performed a microarray analysis and found that many antioxidative stress genes were upregulated in the Keap1-kd-derived tumors. Therefore, we suggest that Nrf2 activation in cancer cells enhances their tumorigenicity, but global Nrf2 activation, as in Keap1-kd mice, simultaneously enhances anticancer immunity, thereby suppressing the growth potential of Keap1-kd tumors. Our findings provide relevant insight into the dual role of Nrf2 in cancer and warrant further studies of Nrf2 function during different stages of carcinogenesis. Cancer Res; 76(10); 3088-96. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27020858     DOI: 10.1158/0008-5472.CAN-15-1584

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

Review 1.  NRF2 and the Hallmarks of Cancer.

Authors:  Montserrat Rojo de la Vega; Eli Chapman; Donna D Zhang
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

2.  IL-11 contribution to tumorigenesis in an NRF2 addiction cancer model.

Authors:  H Kitamura; Y Onodera; S Murakami; T Suzuki; H Motohashi
Journal:  Oncogene       Date:  2017-07-17       Impact factor: 9.867

Review 3.  p62/SQSTM1-Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer.

Authors:  Koji Taniguchi; Shinichiro Yamachika; Feng He; Michael Karin
Journal:  FEBS Lett       Date:  2016-08-06       Impact factor: 4.124

Review 4.  The A to Z of modulated cell patterning by mammalian thioredoxin reductases.

Authors:  Markus Dagnell; Edward E Schmidt; Elias S J Arnér
Journal:  Free Radic Biol Med       Date:  2017-12-24       Impact factor: 7.376

5.  Regulation of Nrf2 Signaling.

Authors:  Robert Li; Zhenquan Jia; Hong Zhu
Journal:  React Oxyg Species (Apex)       Date:  2019-11

Review 6.  Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2 system during cellular stress.

Authors:  Takafumi Suzuki; Masayuki Yamamoto
Journal:  J Biol Chem       Date:  2017-08-24       Impact factor: 5.157

7.  Nrf2 regulates cellular behaviors and Notch signaling in oral squamous cell carcinoma cells.

Authors:  Hong Fan; Chorlada Paiboonrungruan; Xinyan Zhang; Justin R Prigge; Edward E Schmidt; Zheng Sun; Xiaoxin Chen
Journal:  Biochem Biophys Res Commun       Date:  2017-08-15       Impact factor: 3.575

8.  Nrf2 Deficiency Promotes Melanoma Growth and Lung Metastasis.

Authors:  Hong Zhu; Zhenquan Jia; Michael A Trush; Y Robert Li
Journal:  React Oxyg Species (Apex)       Date:  2016-05-30

Review 9.  Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target.

Authors:  Shaohua Ma; Chorlada Paiboonrungruan; Tiansheng Yan; Kevin P Williams; M Ben Major; Xiaoxin Luke Chen
Journal:  Ann N Y Acad Sci       Date:  2018-05-11       Impact factor: 5.691

10.  Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.

Authors:  Youngtae Jeong; Jessica A Hellyer; Henning Stehr; Ngoc T Hoang; Xiaomin Niu; Millie Das; Sukhmani K Padda; Kavitha Ramchandran; Joel W Neal; Heather Wakelee; Maximilian Diehn
Journal:  Clin Cancer Res       Date:  2019-09-23       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.